← Product Code [LZC](/productcode/LZC) · K990677

# ABSOGEL CHEMOTHERAPHY GLOVES (K990677)

_Ampri Rubberware Industries Sdn Bhd · LZC · Nov 1, 1999 · General Hospital · SESE_

**Canonical URL:** https://fda-staging.innolitics.com/device/K990677

## Device Facts

- **Applicant:** Ampri Rubberware Industries Sdn Bhd
- **Product Code:** [LZC](/productcode/LZC.md)
- **Decision Date:** Nov 1, 1999
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 880.6250
- **Device Class:** Class 1
- **Review Panel:** General Hospital

## Indications for Use

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. The extra thickness of this glove is suitable for use in an environment of higher risks, such as Paramedics, Emergency Room, etc. This glove may also provide additional protection in other areas where users are handling certain hazardous chemicals such as chemotherapy drugs, as penetration and permeation to these chemicals are prevented.

## Device Story

Absogel Powder Free Latex Examination Gloves; disposable, non-sterile latex gloves. Designed with extra thickness for high-risk clinical environments (e.g., paramedics, emergency rooms). Provides barrier protection against patient-to-examiner contamination and chemical permeation/penetration when handling hazardous substances, specifically chemotherapy drugs. Operated by healthcare personnel during routine examinations or procedures involving hazardous agents. Benefits include reduced risk of cross-contamination and enhanced protection against chemical exposure for the wearer.

## Clinical Evidence

No clinical data provided. Substantial equivalence is based on bench testing and performance specifications for latex examination gloves, including protein content levels and chemical permeation testing.

## Technological Characteristics

Material: Latex. Form factor: Powder-free examination glove. Features: Extra thickness for high-risk environments. Performance: Tested for use with chemotherapy drugs; protein content 50 micrograms or less.

## Regulatory Identification

A non-powdered patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. A non-powdered patient examination glove does not incorporate powder for purposes other than manufacturing. The final finished glove includes only residual powder from manufacturing.

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the top half of the circle. The bottom half of the circle contains a stylized image of a bird or other winged creature. The image is black and white.

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV - 1 1999

Ms. Phnq Li Kim Director of Operation and Administration AMPri Rubberware Industries Sdn. Bhd. Lot Nos. B5 & B6, Kawasan Perindustrian MIEL Batang Kali Phase II, 44300 Batang Kali, Selangor, MALAYSIA

Re : K990677 Trade Name: Absogel Powder Free Latex Examination Gloves with Tested For Use With Chemotherapy Drugs & Protein Content (50 micrograms or less) Labeling Claims Regulatory Class: I Product Code: LYY August 18, 1999 Dated: Received: Auqust 20, 1999

Dear Ms. Phnq Li Kim:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosurc) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. ರಿ substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in

{1}------------------------------------------------

Page 2 - Ms. Phnq Li Kim

the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.

This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Timothy A. Ulatowski

y A. Ulatowsk Director Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

of Page 1 1

510(k) Number (if known); K990677

Device Name: Absogel Powder Free Latex Examination Gloves with Protein Content (50 micrograms or less) and Chemotherapy Drug Protection Claims

Indications For Use:

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner. The extra thickness of this glove is suitable for use in an environment of higher risks, such as Paramedics, Emergency Room, etc.

This glove may also provide additional protection in other areas where users are handling certain hazardous chemicals such as chemotherapy drugs, as penetration and permeation to these chemicals are prevented.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONȚINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109) OR

Over-The-Counter Use

Image /page/2/Picture/13 description: The image contains a handwritten letter 'X' next to the letter 'e'. The 'X' is larger than the 'e' and is positioned to the right of it. The 'X' is formed by two intersecting diagonal lines, and the 'e' is a lowercase letter with a curved shape.

(Optional Format 1-2-96)

Thien S. Lin

(Division Sign-Off Division of Dental, Infe and General Hospi 510(k) Number

---

**Source:** [https://fda-staging.innolitics.com/device/K990677](https://fda-staging.innolitics.com/device/K990677)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com